News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Deals
NxStage Medical, Inc. Cuts Expected IPO Price Range
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON, Oct 26 (Reuters) - Medical device company NxStage Medical Inc. cut the expected price for its initial public offering to between $11 and $12 a share from a previous range of $13 to $15, according to a regulatory filing on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
IPO
MORE ON THIS TOPIC
Mergers & acquisitions
Concentra Snags Another Struggling Biotech as Cargo Accepts $200M Buyout
July 8, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Sage’s Search for Lifeline Ran Into Defiant Biogen CEO
July 3, 2025
·
3 min read
·
Annalee Armstrong
Deals
Bluebird Go-Private Deal Signals the ‘PE-ization of Pharma’
July 2, 2025
·
7 min read
·
Annalee Armstrong
Mergers & acquisitions
June’s Busy Buyout Binge Bolsters M&A Stats for H1
July 1, 2025
·
4 min read
·
Annalee Armstrong
